Citations as recorded by:

1. Risk of Serious Infection in Juvenile Idiopathic Arthritis Patients Associated With Tumor Necrosis Factor Inhibitors and Disease Activity in the German Biologics in Pediatric Rheumatology Registry

Arthritis Care & Research, 2017, 69(4) p. 552

DOI: 10.1002/acr.22961

Citations as recorded by: Cross Ref

2. Efficacy of biologic therapy across individual juvenile idiopathic arthritis subtypes: A systematic review

Seminars in Arthritis and Rheumatism, 2017, 46(5) p. 584

DOI: 10.1016/j.semarthrit.2016.10.008

Citations as recorded by: Cross Ref

3. Long-term safety and efficacy of etanercept in children and adolescents with plaque psoriasis

Journal of the American Academy of Dermatology, 2016, 74(2) p. 280

DOI: 10.1016/j.jaad.2015.09.056

Citations as recorded by: Cross Ref

4. Effectiveness and long-term retention of anti-tumour necrosis factor treatment in juvenile and adult patients with juvenile idiopathic arthritis: data from Reuma.pt

Rheumatology, 2016, 55(4) p. 697

DOI: 10.1093/rheumatology/kev398

Citations as recorded by: Cross Ref

5. Recent advances in the use of Anti-TNFα therapy for the treatment of juvenile idiopathic arthritis

Expert Review of Clinical Immunology, 2016, 12(6) p. 641

DOI: 10.1586/1744666X.2016.1146132

Citations as recorded by: Cross Ref

6. Biologic-Associated Infections in Pediatric Rheumatology

Curr Rheumatol Rep, 2015, 17(11)

DOI: 10.1007/s11926-015-0542-z

Citations as recorded by: Cross Ref

7. Safety of biologic therapies for the treatment of juvenile idiopathic arthritis

Expert Opinion on Drug Safety, 2015, 14(7) p. 1111

DOI: 10.1517/14740338.2015.1042453

Citations as recorded by: Cross Ref

8. Treatment of juvenile idiopathic arthritis: a revolution in care

Pediatr Rheumatol Online J, 2014, 12 p. 13

DOI: 10.1186/1546-0096-12-13

Citations as recorded by: PMC

9. 2013 Update of the 2011 American College of Rheumatology Recommendations for the Treatment of Juvenile Idiopathic Arthritis: Recommendations for the Medical Therapy of Children With Systemic Juvenile Idiopathic Arthritis and Tuberculosis Screening Among C

Arthritis & Rheumatism, 2013, 65(10) p. 1551

DOI: 10.1002/acr.22087

Citations as recorded by: Cross Ref PMC

10. 2013 Update of the 2011 American College of Rheumatology Recommendations for the Treatment of Juvenile Idiopathic Arthritis: Recommendations for the Medical Therapy of Children With Systemic Juvenile Idiopathic Arthritis and Tuberculosis Screening Among C

Arthritis & Rheumatism, 2013, 65(10) p. 2499

DOI: 10.1002/art.38092

Citations as recorded by: Cross Ref PMC

11. Infections in Children and Adolescents With Juvenile Idiopathic Arthritis and Inflammatory Bowel Disease Treated With Tumor Necrosis Factor-  Inhibitors: Systematic Review of the Literature

Clinical Infectious Diseases, 2013, 57(9) p. 1318

DOI: 10.1093/cid/cit489

Citations as recorded by: Cross Ref PMC

12. The use of biologic response modifiers in polyarticular-course juvenile idiopathic arthritis: A systematic review

Seminars in Arthritis and Rheumatism, 2013, 42(6) p. 597

DOI: 10.1016/j.semarthrit.2012.10.006

Citations as recorded by: Cross Ref

13. Treatment of Juvenile Idiopathic Arthritis in the Biologic Age

Rheumatic Disease Clinics of North America, 2013, 39(4) p. 751

DOI: 10.1016/j.rdc.2013.05.004

Citations as recorded by: Cross Ref

14. Long-term experience with biologic therapies for the treatment of polyarticular juvenile idiopathic arthritis

Clinical Investigation, 2013, 3(5) p. 493

DOI: 10.4155/cli.13.28

Citations as recorded by: Cross Ref